Activin, TGF-β and menin in pituitary tumorigenesis

Advances in Experimental Medicine and Biology

Volumn 668, Issue , 2009, Pages 69-78

  Lebrun, Jean Jacques ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVIN; METHIONINE; SMAD PROTEIN; TRANSFORMING GROWTH FACTOR BETA; MEN1 PROTEIN, HUMAN; ONCOPROTEIN; PROLACTIN;

ADENOHYPOPHYSIS; ARTICLE; CANCER GENETICS; CANCER INHIBITION; CARCINOGENESIS; GENE EXPRESSION; GENE MUTATION; GENE REPRESSION; HORMONAL REGULATION; HUMAN; HYPOPHYSIS ADENOMA; HYPOPHYSIS CELL; MEN1 GENE; MOLECULAR MECHANICS; MULTIPLE ENDOCRINE NEOPLASIA; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR GENE; ADENOMA; GENE EXPRESSION REGULATION; GENETICS; HYPOPHYSIS TUMOR; METABOLISM; PATHOLOGY; PHYSIOLOGY; REVIEW;

ACTIVINS; ADENOMA; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; PITUITARY NEOPLASMS; PROLACTIN; PROTO-ONCOGENE PROTEINS; SIGNAL TRANSDUCTION; SMAD PROTEINS; TRANSFORMING GROWTH FACTOR BETA;

EID: 77950344337     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4419-1664-8_7     Document Type: Article

References (85)

1. Heaney AP, MelmedS. Molecular targets in pituitary tumours. Nat Rev Cancer2004; 4:285-295. (Pubitemid 38525284)
2. Ben-Jonathan N, HnaskoR. Dopamine as a prolactin (PRL) inhibitor. Endocr Rev 2001; 22:724-763. (Pubitemid 34214293)
3. Asa SL, Ezzat S. The cytogenesis and pathogenesis of pituitary adenomas. Endocr Rev 1998; 19:798-827. (Pubitemid 128506522)
4. KajiH, CanaffL, LebrunJJet al. Inactivationof menin, a Smad3-interactingprotein, blocks transforming growth factor type e signaling. ProcNatl Acad Sci USA2001; 98:3837-3842. (Pubitemid 32249858)
5. Lacerte A, Lee EH, Reynaud Ret al. Activin inhibits pituitary prolactin expression and cell growth through Smads, Pu-1 and menin. Mol Endocrinol2004; 18:1558-1569. (Pubitemid 38692190)
6. Faglia G. Epidemiology and pathogenesis of pituitary adenomas. Acta Endocrinol (Copenh) 1993; 129 (Suppl 1):1-5. (Pubitemid 23236053)
7. Shimon 1, Melmed S. Genetic basisof endocrine disease: Pituitary tumor pathogenesis. J Clin Endocrinol Metab 1997; 82:1675-168.I.
8. Spada A, Vallar L, Faglia G. G-proteins and hormonal signalling in human pituitary tumors: Genetic mutations and functional alterations. Frontiers in Neuroendocrinology 1993; 14:214-232. (Pubitemid 23195793)
9. Ledenr C, Parma J, Pirson I et al. Positive control of proliferation by the cyclic AMP cascade: An oncogenic mechanism of hyper-functional adenoma. J Endocrinol Invest 1995; 18:120-122.
10. Weil RJ, Vortrneyer AO, Huang S et al. 11q13allelic loss in pituitary tumors in patients with multiple endocrine neoplasia syndrome type 1. Clin Cancer Res 1998; 4:1673-1678. (Pubitemid 28304728)
11. Eubanks PJ, Sawicki MP, Samara GJet al. Putative tumor-suppressor gene on chromosome 11 is important in sporadic endocrine tumor formation. Am J Surg 1994; 167:180-185. (Pubitemid 24264162)
12. Wautot Y, Vercherat C, LespinasseJet al. Germline mutation pro61e of MENI in multiple endocrine neoplasia type 1: Search for correlation between phenotype and the functional domains of the MEN1 protein. Hum Murat 2002; 20:35-47. (Pubitemid 34747715)
13. Boggild MD, Jenkinson S, Pistorello M et al. Molecular genetic studies of sporadic pitu itary tumors. J Clin Endocrinol Metab 1994;78:387-392. (Pubitemid 24061758)
14. Thakker RY, Pook MA, Wooding C et al. Association of somatotrophinomas with loss of alleles on chromosome 11 and with gsp mutations, J Clin Invest 1993; 91:2815-282.I. (Pubitemid 23182540)
15. Herman V, Fagin J, Gonsky Ret al. Clonal origin of pituitary adenomas. J Clin Endocrinol Metab 1990; 71:1427-1433. (Pubitemid 120032755)
16. Bates AS, FarrellWE, BicknellEJet al. Allelicdeletion in pituitary adenomas reflects aggressive biological activity and has potential value as a prognostic marker. J Clin Endocrinol Metab 1997;82:818-824. (Pubitemid 27106594)
17. Dong Q. Debelenko LV, Chandrasekharappa SCet al. Loss of heterozygosity at 11q13: Analysis of pituitary tumors, lung carcinoids, lipomas and other uncommon tumors in subjects with familial multiple endocrine neoplasia type 1.J Clin Endocrinol Metab 1997; 82:1416-1420. (Pubitemid 27200411)
18. Crabtree JS, Scacheri PC, Ward JMet al. A mouse model of multiple endocrine neoplasia, type 1, develops multiple endocrine tumors. Proc Nad Acad Sci USA 2001; 98:1118-1123. (Pubitemid 32121196)
19. Zhuang Z, Ezzat SZ, Vortmeyer AO et al. Mutations of the MENI tumor suppressor gene in pituitary tumors, Cancer Res 1997; 57:5446-545.I. (Pubitemid 28006744)
20. Poncin J, Srevenaert A, Beckers A. Somatic MEN 1 gene mutation does not contribute signi6candy to sporadic pituitary tumorigenesis. Eur J Endocrinol 1999; 140:573-576. (Pubitemid 29314720)
21. Theodoropoulou M, Cavallari 1, Barzon Let al. Differential expression of menin in sporadic pituitary adenomas. Endocr Relat Cancer 2004; 11:333-344. (Pubitemid 38832834)
22. Burgess J, Shepherd J, Parameswaran Vet al. Prolactinomas in a large kindred with multiple endocrine neoplasia type 1: Clinical features and inheritanc e pattern. J Clin Endocrinol Metab 1996; 81:1841-1845. (Pubitemid 26152473)
23. Verges B, Boureille F, Goudet Pet al. Pituitary disease in MEN type 1 (MEN 1): Data from the France-Belgium MENI multicenter study. J Clin Endocrinol Metab 2002; 87:457-465. (Pubitemid 34158204)
24. Beckers A, Berea D, Socin HV et al. The treatment of sporadic versus MENI-related pituitary adenomas.J Intern Med 2003; 253:599-605. (Pubitemid 36649091)
25. Massague J. The transforming growth factor-13 family. Annu Rev Cell Bioi 1990; 6:597-64.I.
26. Massague J. TGF-13 signal transduction. Annu Rev Biochem 1998;67:753-79.I.
27. Vale W; Rivier J, Vaughan J et al. Purification and characterization of an FSH releasing protein from porcine ovarian follicular fluid. Nature 1986; 321:776-779. (Pubitemid 16077904)
28. Ling N, Ying SY,Ueno Net al. Pituitary FSH is released by a heterodlmer of the 13-subunits from the two forms of inhibin. Nature 1986; 321:779-782. (Pubitemid 16077905)
29. Vale W; Rivier C, Hsueh A et al. Chemical and biological characterization of the inhibin family of protein hormones, Recent Prog Horm Res 1988;44:1-34.
30. Chen YG, Lui HM, Lin SL et al. Regulation of cell proliferation, apoptosis and carcinogenesisby activin.Exp Biol Med (Maywood) 2002; 227:75-87.
31. Lebrun JJ, Valeww. Activin and inhibin have antagonistic effectson ligand-dependent heteromerization of the type 1 and type 1I activin receptors and human erythroid differentiation, Mol Cell Biol 1997; 17:1682-169.I. (Pubitemid 27097397)
32. McCarthy SA, Bicknell R. Inhibition of vascular endothelial cell growth by activin-A. J Bioi Chern 1993; 268:23066-2307.I. (Pubitemid 23328013)
33. Brosh N, Sternberg D, Honigwachs-Sha'anani Jet al. The plasmacytoma growth inhibitor resrrictin-P is an antagon ist of interleukin 6 and interleukin 1I. Identi6cation as a stroma-derived activin A. J Biol Chern 1995; 270:29594-29600.
34. Valderrama-Carvajal H, Cocolakis E, Lacerte Aet al. Activin /TGF-13 induce apoptosis through Smad-dependent expression of the lipid phosphatase SHIP. Nat Cell Bioi 2002; 4:963-969. (Pubitemid 35469426)
35. Kalkhoven E, Roelen BA, de Winter JP et al. Resistance to transforming growth factor e and activin due to reduced receptor expression in human breast tumor cell lines. Cell Growth Differ 1995; 6:1151-116.I.
36. Liu QY, Niranjan B, Gomes Pet al. Inhibitory effects of activin on the growth and morpholgenesis of primary and transformed mammary epithelial cells. Cancer Res 1996; 56:1155-1163. (Pubitemid 26065416)
37. Cocolakis E, Lemay S, Ali Set al. The p38 MAPK pathway is required for cell growth inhibition of human breast cancer cells in response to activin, J Bioi Chern 2001; 276:18430-18436.
38. Yasuda H, Mine T, Shibata H et al. Activin A: An autocrine inhibitor of initiation of DNA synthesis in rat hepatocytes. J Clin Invest 1993; 92:1491-1496. (Pubitemid 23273929)
39. XUJ, McKeehan K, Matsuzaki K et al. Inhibin antagonizes inhibition of liver cell growth by activin by a dominant-negative mechanism. J Bioi Chern 1995; 270:6308-6313.
40. Zauberman A, Oren M, Zipori D. Involvement of p2I(WAFl/Cipl), CDK4 and Rb in activin A mediated signaling leading to hepatoma cell growth inhibition. Oncogene 1997; 15:1705-171.I. (Pubitemid 27466710)
41. Takabe K, Lebrun JJ, Nagashima Y et al. Interruption of activin A autocrine regulation by antisense oligodeoxynucleondes accelerates liver tumor cell proliferation. Endocrinology 1999; 140:3125-3132. (Pubitemid 30650627)
42. Chen W; WoodruffTK, Mayo KE. Activin A-induced HepG2 liver cell apoptosis: Involvement of activin recepto rs and smad proteins, Endocrinology 2000; 141:1263-1272. (Pubitemid 32260471)
43. Ho J, de Guise C, Kim Cet al. Activin induces hepatocyte cell growth arrest through induction of the cyclin-dependent kinase inhibitor p15INK4B and SpI. Cell Signal 2004; 16:693-70.I. (Pubitemid 38490551)
44. Zhou Y, Sun H, Danila DC et al. Truncated activin type 1 receptor Alk4 isoforms are dominant negative receptors inhibiting activin signaling. Mol Endocrinol 2000; 14:2066-2075,
45. Shi Y,Wang YF, Jayaraman Let al. Crystal structure of a Smad MH1 domain bound to DNA: Insights on DNA binding in TGF-e signaling. Cell 1998; 94:585-594. (Pubitemid 28427577)
46. Massague J, Wotton D. Transcriptional control by the TGF-e/Smad signaling system. EMBO J 2000; 19:1745-1754. (Pubitemid 30204386)
47. Chen X, Weisberg E, Fridmacher V et al. Smad4 and FAST-l in the assembly of activin-responsive factor. Nature 1997; 389:85-89. (Pubitemid 27387696)
48. Hata A, Seoane J, Lagna G et al. OAZ uses distinct DNA-And protein-binding zinc lingers in separate BMP-Smad and Olf signaling pathways. Cell 2000; 100:229-240. (Pubitemid 30064911)
49. Hahn SA, Hoque AT, Moskaluk CAet al. Homozygous deletion map at 18q2I.1 in pancreatic cancer.Cancer Res 1996; 56: 490-494, (Pubitemid 26043644)
50. Moskaluk CA, Kern SE. Cancer gets Mad: DPC4 and other TGFe pathway genes in human cancer.Biochim Biophys Acta 1996; 1288:M31-33, (Pubitemid 27006531)
51. Hahn SA, Bartsch D, Schroers Aet al. Mutations of the DPC4/Smad4 gene in biliary tract carcinoma.Cancer Res 1998; 58:1124-1126. (Pubitemid 28183196)
52. Eppert K, Scherer SW; Ozcelik Het al. MADR2 maps to 18q21 and encodes a TGFe-regulated MAD-related protein that is functionally mutated in colorectal carcinoma. Cell 1996; 86:543-552. (Pubitemid 26299486)
53. Riggins GJ, Kinzler Kw; Vogelstein Bet al. Frequency of Smad gene mutations in human cancers.Cancer Res 1997; 57:2578-2580. (Pubitemid 27283760)
54. Takagi Y.Koumura H. Futamura M et al. Somatic alteration s of the SMAD-2 gene in human colorectal cancers. Br J Cancer 1998; 78:1152-1155. (Pubitemid 28479142)
55. Uchida K, Nagatake M, Osada Het al. Somatic in vivo alterations of the JV18-1 gene at 18q21 in human lung cancers. Cancer Res 1996; 56:5583-5585, (Pubitemid 26422155)
56. Kim SK, Fan Y, Papadimitrakopoulou Vet al. DPC4, a candidate tumor suppressor gene, is altered infrequently in head and neck squamous cell carcinoma. Cancer Res 1996; 56:2519-252.I. (Pubitemid 26170686)
57. YakicierMC, Irmak MB, Romano Aet al. Smad2 and Smad4 gene mutations in hepatocellular carcinoma.Oncogene 1999; 18:4879-4883, (Pubitemid 29423571)
58. Luisi S, Florio P, Reis Fet al. Expression and secretion of activin A: Possible physiological and clinical implications. Eur J Endocrinology 2001; 145:225-236. (Pubitemid 32825654)
59. Lebrun JJ, Chen Y, ValeWW. Receptor serine kinases and signaling by activins and inhibins. In: Aono T, Sugino H ValeWW eds, Inhibin, activin and follistatin : Regulato ry functions in system and cell biology. New York: Springer-Verlag, 1997:1-2.I.
60. De Guise C, Lacerte A, Raliei S et al. Activin inhibits the human Pit-I gene promoter through the p38 kinase pathway in a Smad-independent manner. Endocrinology 2006; 147:4351-4362. (Pubitemid 44268386)
61. Murata T, Ying S. Transforming growth facror-B and activin inhibit basal secretion of prolactin in a pituitary monolayer culture system. Proc Soc Exp Bioi Med 1991; 198:599-605.
62. Danila DC, Inder WJ, Zhang Xet al. Activin effects on neoplastic proliferation of human pituitary tumors. J Clin Endocrinol Merab 2000; 85:1009-1015, (Pubitemid 32269341)
63. Su GH, Bansal R, Murphy KMet al. ACVRIB (ALK4, activin receptor type 1B) gene mutations in pancreatic carcinoma. Proc Natl Acad Sci USA 2001; 98:3254-3257, (Pubitemid 32220832)
64. Alexander JM, Bikkal HA, Zervas NTet al. Tumor-specific expression and alternate splicing of messenger ribonucleic acid encoding activin/transforming growth factor-e receptors in human pituitary adenomas. J Clin Endocrinol Merab 1996; 81:783-790. (Pubitemid 26055700)
65. Zhou Y, Sun H, Danila DCet al. Truncated activin type 1 receptor Alk4 isoforms are dominant negative receptors inhibiting activin signaling. Mol Endocrinol 2000; 14:2066-2075,
66. Bilezikjian LM, Blount AL, Corrigan AZ et al. Actions of activins, inhibins and follistatins: Implications in anterior pituitary function, Clin Exp Pharmacol Physiol 2001; 28:244-248. (Pubitemid 32193672)
67. Otsuka F,Shimasaki S. A novel function of bone morphogenetic protein-15 in the pituitary: Selective synthesis and secretion of FSH by gonadotropes, Endocrinology 2002; 143:4938-494.I. (Pubitemid 35397634)
68. Lewis KA, Gray PC, Blount ALet al. eglycan binds inhib in and can mediate functional antagonism of activin Signalling. Nature 2000; 404:411-414. (Pubitemid 30164345)
69. Bilezikjian LM, Corrigan AZ, Blount AL et al. Regulation and actions of Smad7 in the modulation of activin, inhibin and transforming growth facror-B signaling in anterior pituitary cells. Endocrinology 2001 ; 142:1065-1072. (Pubitemid 32202815)
70. Bilezikjian LM, Corrigan AZ, Blount ALet al. Pituitary follistatin and inhibin subunir messenger ribonucleic acid levels are differentially regulated by local and hormonal factors. Endocrinology 1996; 137:4277-4284. (Pubitemid 26321876)
71. Abraham EJ, Faught WJ, FrawleyLS. Transforming growth factor e1 is a paracrine inhibitor of prolactin gene expression. Endocrinology 1998; 139:5174-518.I. (Pubitemid 28533467)
72. Cocolakis E, Dai M, Drevet L et al. Smad signaling antagonizes STAT5-mediated gene transcription and mammary epithelial cell differentiation, J Bioi Chern 2008; 283:1293-1307.
73. Bertolino P, Tong WM, Galendo D et al. Heterozygous Men1 mutant mice develop a range of endocrine tumors mimicking multiple endocrine neoplasia type 1. Mol Endocrinol 2003; 17:1880-1892. (Pubitemid 37072302)
74. Bertolino P, Radovanovic I, Casse H et al. Genetic ablation of the tumor suppressor menin causes lethality at mid-gestation with defects in multiple organs. Mech Dev 2003; 120:549-560. (Pubitemid 36623317)
75. Namihira H, Saro M, Murao Ket al. The multiple endocrine neoplasia type 1 gene product, menin, inhibits the human prolactin promoter activity. Journal of Molecular Endocrinology 2002; 29:297-304. (Pubitemid 36024546)
76. Kaji H, CanaffL, Lebrun J-J et al. Inactivation of rnenin, a Smad3-interacting protein, blocks transforming growth factor type 13 signaling. Proc Natl Acad Sci USA 2001; 98:3837-3842. (Pubitemid 32249858)
77. Keech C, Gutierrez-Hartmann A. Analysisof rat prolactin promoter sequences that mediate pituitary-specific and 3', 5'-cyclic adenosine monophosphate-regulated gene expression in vivo. Mol Endocrinol1989; 3:832-839. (Pubitemid 19130106)
78. Keech C, Gutierrez-Hartmann A. Insulin activation of rat prolactin promoter activity. Mol Cell Endocrinol 1991; 78:55-60.
79. Tashjian AH jr, Yasumura Y, Levine Let al. Establishment of clonal strains of rat pituitary tumor cells that secrete growth hormone, Endocrinology 1968; 82:342-352,
80. Song JY, jin L, Lloyd RV. Effects of estradiol on prolactin and growth hormone messenger RNAs in cultured normal and neoplastic (MtT/W15 and GH3) rat pituitary cells. Cancer Res 1989; 49:1247-1253. (Pubitemid 19074845)
81. Sowa H, Kaji H, Hend y GNet al. Menin is required for bone morphogenetic protein 2-And transforming growth factor e-regulated osteoblastic differentiation through interaction with Smads and Runx2. J Bioi Chern 2004; 279:40267-40275, (Pubitemid 39287610)
82. Macias-Silva M, Abdollah S, Hoodless PAet al. MADR2 is a substrate of the TGFe receptor and its phosphorylation is required for nuclear accumulation and signaling. Cell 1996; 87:1215-1224. (Pubitemid 27010105)
83. Liu X, Sun Y,Constantinescu SNet al. Transforming growth factor e-induced phosphorylation of Smad3 is required for growth inhibition and transcriptional induction in epithelial cells. Proc Natl Acad Sci USA 1997; 94:10669-10674.
84. Stroschein SL, Wang W; Zhou S et al. Negative feedback regulation of TGF-e signaling by the SnoN oncoprotein. Science 1999; 286:771-774.
85. Luo K, Stroschein SL, Wang Wet al. The Ski oncoprotein interacts with the Smad proteins to repress TGFe signaling. Genes Dev 1999; 13:2196-2206. (Pubitemid 29426725)